02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
09:15 , Jul 9, 2019 |  BC Extra  |  Financial News

BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in...
22:01 , Jun 17, 2019 |  BC Extra  |  Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
15:54 , Apr 17, 2019 |  BC Extra  |  Financial News

Turning Point gains after pricing upsized $166.5M IPO

Turning Point shares jumped $10.90 (61%) to $28.90 in their first day of trading Wednesday after the company raised $166.5 million in an upsized IPO priced late Tuesday. Turning Point Therapeutics Inc. (NASDAQ:TPTX) sold 9.3...
23:21 , Apr 11, 2019 |  BC Extra  |  Company News

Management tracks: Prime, Flexion, NodThera, Imara

PBM Prime Therapeutics LLC (Eagan, Minn.) hired Kenneth Paulus as president and CEO, effective May 7. Paulus is an executive adviser at Water Street Healthcare Partners. In 2005-15, Paulus held leadership roles at Minneapolis-based non-profit...
13:48 , Mar 22, 2019 |  BC Extra  |  Financial News

Oncology company Turning Point seeking $100M IPO

Five months after raising an $80 million mezzanine round, cancer company Turning Point is aiming to reap $100 million in a NASDAQ listing that will fund a registrational trial. Turning Point Therapeutics Inc. (San Diego,...